New England Biolabs Executive and Leadership Team

Salvatore Russello, the Chief Executive Officer at New England Biolabs, directs the overarching strategic vision for the production and supply of enzyme reagents. Overseeing the global expansion of life science research solutions, the Chief Executive Officer ensures that the company maintains a competitive edge in synthetic biology and next-generation sequencing markets. This leadership role involves constant collaboration with the Board to align operational output with the evolving needs of the scientific community. By prioritizing innovation in recombinant technology, Salvatore Russello drives the long-term growth trajectory of the organization. The Chief Executive Officer also manages the integration of research tools like REBASE into the broader corporate portfolio. Through rigorous oversight of manufacturing standards, the Chief Executive Officer guarantees that the company remains a trusted partner for researchers worldwide. Ultimately, Russello secures the market position of the firm by fostering a culture of scientific excellence and operational efficiency across all international divisions.

Richard Ireland, the Chief Financial Officer at New England Biolabs, manages the fiscal health and capital allocation strategies required to support the manufacturing of enzyme reagents. Overseeing the financial planning and analysis departments, the Chief Financial Officer ensures that resources remain directed toward high-impact research and development projects. This leadership role involves maintaining robust financial controls while supporting the global supply chain operations that define the company's market presence. By optimizing cost structures and revenue streams, Richard Ireland directly impacts the ability of the firm to provide free access to critical research databases. The Chief Financial Officer also coordinates with executive leadership to evaluate investment opportunities in genome editing and synthetic biology. Through disciplined fiscal management, the Chief Financial Officer sustains the long-term viability of the organization. Ultimately, Ireland provides the financial stability necessary for the company to continue delivering essential tools to the life science research community.

Hiroshi Toshishige, the Neb Inc President & General Manager (Japan) at New England Biolabs, directs all commercial operations and market expansion efforts throughout the Asian region. Overseeing the distribution of recombinant and native enzyme reagents, the Neb Inc President & General Manager (Japan) ensures that local research institutions receive the necessary support for genome editing and synthetic biology projects. This leadership role involves tailoring the company's global strategy to meet the specific demands of the Japanese life science market. By fostering strong relationships with academic and industrial partners, Hiroshi Toshishige drives revenue growth and brand recognition in this critical territory. The Neb Inc President & General Manager (Japan) also coordinates with the headquarters to streamline supply chain logistics and product availability. Through effective regional management, the Neb Inc President & General Manager (Japan) strengthens the company's international footprint. Ultimately, Toshishige ensures that the firm remains the preferred provider of research tools within the region.

Lennox Brown, the Chief Information Officer & Director, Information Technology at New England Biolabs, architects the digital infrastructure supporting the company's complex enzyme reagent manufacturing processes. Overseeing the maintenance of critical research databases like REBASE, InBASE, and Polbase, the Chief Information Officer & Director, Information Technology ensures seamless data accessibility for the global scientific community. This leadership role involves implementing secure, scalable systems that facilitate next-generation sequencing workflows and synthetic biology research. By modernizing the technological framework, Lennox Brown drives operational efficiency and data integrity across all departments. The Chief Information Officer & Director, Information Technology also collaborates with other executives to integrate advanced analytics into the product development cycle. Through the deployment of robust cybersecurity measures, the Chief Information Officer & Director, Information Technology protects the intellectual property of the firm. Ultimately, Brown enables the digital transformation required to maintain the company's status as a leader in life science reagents.